戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 pioid antagonists, naloxone, naltrexone, and nalmefene.
2 ncytial virus 24 hrs after the first dose of nalmefene.
3 s further enhanced when co-administered with nalmefene.
4 eatment with an initial ameliorating dose of nalmefene.
5 melioration of the perception of pruritus on nalmefene.
6 and 24 hr after the administration of either nalmefene (1 mg or 1 microg/kg) or naloxone (2 mg or 2 m
7 ed (1:1) to 24 weeks of as-needed placebo or nalmefene 18 mg.
8                    The effect of single dose nalmefene (18 mg) on changes in a priori defined striata
9                                     Low-dose nalmefene (25 mg/day) appeared efficacious and was assoc
10 l gambling were randomly assigned to receive nalmefene (25 mg/day, 50 mg/day, or 100 mg/day) or place
11 ix hundred and four patients (placebo = 298; nalmefene = 306),>/=18 years of age, with a diagnosis of
12 2.4 times greater with placebo compared with nalmefene (95% confidence interval, 1.05-5.59).
13 hat nalfurafine (a G-biased KOR agonist) and nalmefene (a KOR partial agonist) also produced long-las
14             Animals were injected daily with nalmefene, a nonselective opioid receptor antagonist, an
15                                              Nalmefene, a pure opiate antagonist with a longer durati
16                   These results suggest that nalmefene administration produces transient changes in t
17                            Following chronic nalmefene administration, no significant change in eithe
18 Oral administration of the opioid antagonist nalmefene alone (up to 20 mg/kg) failed to show a signif
19                        Patients treated with nalmefene also had fewer subsequent relapses (P<.03) tha
20 d receptors were 28.7 +/- 5.9 hr for 1 mg of nalmefene and 2.0 +/- 1.6 hr for 2 mg of naloxone.
21 times slower than plasma clearance times for nalmefene and naloxone, respectively.
22             However, combined oral dosing of nalmefene and subthreshold doses of AM251, a cannabinoid
23 led clinical trials of naloxone, naltrexone, nalmefene, and buprenorphine in patients with schizophre
24 cutaneous administration of opioid antidote, nalmefene, and transmission of a GPS-trackable 911 alert
25 oid overdose antidotes such as naloxone, and nalmefene are available, these must be administered with
26 ndings suggest that the prolonged effects of nalmefene are related to the slow dissociation of nalmef
27        Daily microdosing with nalfurafine or nalmefene blocked KORs responsible for antinociceptive e
28                                              Nalmefene blunts BOLD response in the mesolimbic system
29 rugs and that the pharmacokinetic profile of nalmefene can be tuned by varying the length of the alky
30 t Month 6, there was a significant effect of nalmefene compared with placebo in reducing the number o
31  therefore demonstrate that sustained plasma nalmefene concentrations can be achieved in both dog and
32 er was chosen to demonstrate that dog plasma nalmefene concentrations were dose-dependent at 1, 5 and
33 at a dose of 5mg-eq. nalmefene/kg and plasma nalmefene concentrations were measured over a four-week
34 eries of studies, three different lipophilic nalmefene derivatives were evaluated: the palmitate (C16
35                                              Nalmefene did not alter brain perfusion.
36 e the safety and efficacy of 2 doses of oral nalmefene for alcohol dependence.
37 fene are related to the slow dissociation of nalmefene from opioid receptors, which are not reflected
38 ression and liver enzymes were larger in the nalmefene group compared with placebo at Week 24.
39 gnment to the placebo or 20- or 80-mg/d dose nalmefene groups for 12 weeks.
40 ents showed that the 25 mg/day and 50 mg/day nalmefene groups had significantly different scores on t
41 id not differ between the 20- and 80-mg dose nalmefene groups.
42                        Subjects who received nalmefene had a statistically significant reduction in s
43                         Both nalfurafine and nalmefene have long histories of safety and use in human
44 improvement in some consumption outcomes for nalmefene (heavy drinking days per month: WMD, -2.0; 95%
45 cerebral mu opioid receptors by naloxone and nalmefene in eight normal volunteers.
46 as-needed use of the opioid system modulator nalmefene in reducing alcohol consumption in patients wi
47 cy and tolerability of the opioid antagonist nalmefene in the treatment of adults with pathological g
48                      Neither nalfurafine nor nalmefene is a completely selective KOR ligand, but KOR
49                                              Nalmefene is a micro and delta opioid receptor antagonis
50                                              Nalmefene is a newer opioid antagonist that is structura
51                                              Nalmefene is an opioid antagonist which as a once-a-day
52 oral administration of the opiate antagonist nalmefene is associated with any beneficial effects in p
53 n dogs and in minipigs, at a dose of 5mg-eq. nalmefene/kg and plasma nalmefene concentrations were me
54 ons were dose-dependent at 1, 5 and 20mg-eq. nalmefene/kg.
55 n a sesame oil solution at a dose of 1mg-eq. nalmefene/kg.
56                   These results suggest that nalmefene may have a favorable risk-to-benefit ratio whe
57 livered a fairly constant level of 0.2-0.3ng nalmefene/mL plasma for one month and since there was no
58 taking placebo (n = 289) and patients taking nalmefene (n = 290) were included in the efficacy analys
59                           For naltrexone and nalmefene, NNHs for withdrawal from trials due to advers
60                        Possible tolerance to nalmefene occurred in 3 patients.
61                     Effects of naltrexone or nalmefene on alcohol intake were examined in continuous
62  to determine the effect of a single dose of nalmefene on striatal blood oxygen level-dependent (BOLD
63 nic administration of the opioid antagonist, nalmefene, on the binding activity of [11C]SCH23390 and
64 ed either a single injection of 10 (mg/kg of nalmefene or control vehicle solution 1 h prior to the P
65 ere chronically administered 10 mg/kg/day of nalmefene or vehicle for 7 days by an osmotic minipump.
66 an be achieved in both dog and minipig using nalmefene prodrugs and that the pharmacokinetic profile
67 is patient population, a number of potential nalmefene prodrugs were synthesized with the aim of prov
68                                              Nalmefene provides clinical benefit, constitutes a poten
69  This longer blockade of opioid receptors by nalmefene represents an advantage in the clinical manage
70                      This is consistent with nalmefene's actions on opioid receptors, which modulate
71 hat in the presence of the alcohol infusion, nalmefene significantly reduced the BOLD response in the
72    Significantly fewer patients treated with nalmefene than patients given placebo relapsed to heavy
73  due to adverse events were more common with nalmefene than placebo.
74            Following acute administration of nalmefene, the binding potential of [11C]SCH23390 in the
75  were higher than corresponding means during nalmefene therapy in 13 (P = .002) and 12 (P = .013) pat
76 ienced marked exacerbation of pruritus after nalmefene therapy was suddenly discontinued.
77 action that did not preclude continuing with nalmefene therapy.
78                                     In mice, nalmefene treatment increased viral titers and was assoc
79                               Treatment with nalmefene was effective in preventing relapse to heavy d
80                              Blood levels of nalmefene were consistent with normal pharmacokinetics o
81               Similarly, both naltrexone and nalmefene were more effective in suppressing operant alc
82 2% of the subjects who received 25 mg/day of nalmefene were rated as "much improved" or "very much im
83                                  The dose of nalmefene, which initially was 2 mg orally twice daily,